3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
8
Unknown
7
Recruiting
3
Active not recruiting
3
Withdrawn
1
Enrolling by invitation
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
5
Tongue Neoplasms
4
Head and Neck Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Squamous Cell
1
Mucositis
1
Mouth Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Paclitaxel
28
Trastuzumab
22
Cyclophosphamide
21
Doxorubicin
14
Docetaxel
14
Carboplatin
11
exemestane
10
Radiotherapy
10
Letrozole
10
Capecitabine
10
pembrolizumab
8
Lapatinib
8
Fulvestrant
8
Neoadjuvant Therapy
6
Goserelin
6
Bevacizumab
6
Anastrozole
6
pertuzumab
5
palbociclib
5
eribulin
5
abemaciclib
5
Therapeutics
5
Magnetic Resonance Spectroscopy
5
Epirubicin
5
Chemotherapy, Adjuvant
5
Aromatase Inhibitors
5
tucatinib
4
Vinorelbine
4
Taxes
4
Tamoxifen
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Breast Neoplasms
×
Radiotherapy, Intensity-Modulated
×
Clear all
NCT02079272
2015-04-06
REBECCA
Institut de Radioprotection et de Surete Nucleaire
Phase NA
Withdrawn